Candel Therapeutics (CADL) Non-Current Assets (2020 - 2025)
Candel Therapeutics (CADL) posted Non-Current Assets of $3.8 million for Q4 2025, up 9.87% sequentially from $3.5 million in Q3 2025, and up 24.3% YoY from $3.1 million in Q4 2024.
Candel Therapeutics (CADL) Non-Current Assets (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Non-Current Assets for 6 years, with the latest figure at $3.8 million in Q4 2025.
- Quarterly Non-Current Assets rose 24.3% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.4 million (down 13.53% YoY) and the FY2025 annual result came in at $3.8 million, up 24.3% from the prior year.
- Non-Current Assets advanced to $3.8 million in Q4 2025 per CADL's latest filing, from $3.5 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $6.3 million in Q2 2021 and troughed at $2.4 million in Q2 2025.
- A 5-year average of $4.5 million and a median of $4.4 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2025: Non-Current Assets soared 35.84% in 2021, then plunged 37.07% in 2025.
- Over 5 years, Non-Current Assets stood at $4.3 million in 2021, then soared by 34.88% to $5.7 million in 2022, then retreated by 23.36% to $4.4 million in 2023, then slumped by 30.47% to $3.1 million in 2024, then climbed by 24.3% to $3.8 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $3.8 million, $3.5 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 3.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.81 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | 2.36 Mn |
| Mar 31, 2025 | 2.76 Mn |
| Dec 31, 2024 | 3.06 Mn |
| Sep 30, 2024 | 3.43 Mn |
| Jun 30, 2024 | 3.75 Mn |
| Mar 31, 2024 | 4.08 Mn |
| Dec 31, 2023 | 4.40 Mn |
| Sep 30, 2023 | 4.96 Mn |
| Jun 30, 2023 | 5.35 Mn |
| Mar 31, 2023 | 5.36 Mn |
| Dec 31, 2022 | 5.75 Mn |
| Sep 30, 2022 | 5.94 Mn |
| Jun 30, 2022 | 5.98 Mn |
| Mar 31, 2022 | 5.92 Mn |
| Dec 31, 2021 | 4.26 Mn |
| Sep 30, 2021 | 5.01 Mn |
| Jun 30, 2021 | 6.32 Mn |
| Dec 31, 2020 | 3.14 Mn |